Across TCGA pan-cancer cohorts, RIPPLY3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RIPPLY3 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher RIPPLY3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RIPPLY3 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

UCS and SKCM are the cancer types where RIPPLY3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.007	0.689	<.001	24	view →
SKCM	DFS	Median	II,III,IV	1.000	0.677	.003	18	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: RIPPLY3 tumor-vs-normal RNA expression · all RIPPLY3 data types